secwatch.observer — SEC 8-K summary
======================================

Issuer:     Quantum-Si Inc (QSI)
CIK:        0001816431
Form:       8-K
Filed at:   2023-03-06T23:59:59+00:00
Accession:  0001140361-23-010228
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Quantum-Si reports FY2022 net loss of $132.4M; begins Platinum shipments, expects Q1 2023 revenue
--------------------------------------------------------------------------------

- Q4 2022 net loss $33.1M vs $29.4M in Q4 2021; FY2022 net loss $132.4M vs $95.0M in FY2021.
- Cash and investments $351.3M as of Dec 31, 2022; company projects cash runway into 2026.
- Launched Platinum protein sequencer in Dec 2022; began shipments early Q1 2023; expects first revenue in Q1 2023.
- Non-GAAP operating expenses expected approximately flat in 2023 vs 2022; restructuring to reduce costs.
- Hired Grace Johnston as Chief Commercial Officer; partnered with Aviva Systems Biology and Biovista.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1816431/000114036123010228/0001140361-23-010228-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1816431/000114036123010228/brhc10049258_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-23-010228

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer